Understanding the Role of GLP‑1 in Peri‑operative Glucose Management
Glucagon‑like peptide‑1 (GLP‑1) receptor agonists have become a cornerstone in the treatment of type 2 diabetes and, more recently, obesity. Common brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound are frequently encountered in pre‑operative assessments. While these agents improve glycaemic control under normal circumstances, their influence on glucose monitoring during anesthesia requires careful interpretation.
During surgery, the body’s physiological stress response, the anesthetic agents used, and the patient’s baseline medication regimen all converge to affect blood glucose levels. Clinicians must recognise how GLP‑1 therapy modifies these dynamics to avoid misreading glucose values and to maintain optimal peri‑operative safety.
How GLP‑1 Receptor Agonists Work
GLP‑1 receptor agonists mimic the incretin hormone GLP‑1, which is released by the intestines in response to food intake. Their primary actions include:
- Enhancing glucose‑dependent insulin secretion.
- Suppressing inappropriate glucagon release.
- Slowing gastric emptying, which reduces post‑prandial glucose spikes.
- Promoting satiety, leading to weight loss.
Because these effects are glucose‑dependent, they generally carry a low risk of hypoglycaemia when used alone. However, the peri‑operative environment can alter this balance.
Physiological Changes in Glucose Homeostasis During Anesthesia
General and regional anesthesia trigger a cascade of hormonal changes, including:
- Increased catecholamines (epinephrine, norepinephrine) that raise hepatic glucose production.
- Elevated cortisol and growth hormone, which promote insulin resistance.
- Potential suppression of endogenous insulin secretion, especially with volatile anesthetics.
These responses typically cause hyperglycaemia, but the magnitude varies with the type of surgery, duration, and patient factors such as age and comorbidities.
Interaction Between GLP‑1 Therapy and Anesthetic Agents
When a patient on a GLP‑1 agonist enters the operating room, several interaction points merit attention:
- Gastric Emptying Delay: GLP‑1 slows gastric emptying, which can affect the timing of pre‑operative fasting guidelines. Anesthesiologists should verify that the patient has adhered to an appropriate fasting period to reduce aspiration risk.
- Insulin Secretion Modulation: The glucose‑dependent insulinotropic effect of GLP‑1 may blunt the expected rise in glucose after surgical stress, potentially leading to lower-than‑anticipated intra‑operative glucose readings.
- Risk of Hypoglycaemia with Concurrent Medications: If the patient is also receiving sulfonylureas or insulin, the additive effect of GLP‑1 can increase hypoglycaemia risk, especially during prolonged procedures.
- Pharmacokinetic Considerations: Long‑acting agents such as Ozempic (once‑weekly) maintain therapeutic levels throughout the peri‑operative period, whereas shorter‑acting formulations may be held on the day of surgery without significantly affecting glucose control.
Interpreting Glucose Readings Under Anesthesia
Accurate interpretation of intra‑operative glucose measurements is critical. The following principles help clinicians differentiate between drug‑related effects and genuine metabolic changes:
- Baseline Trend: Review the patient’s pre‑operative glucose trend (e.g., home glucometer logs or recent lab values). A stable baseline suggests that abrupt intra‑operative spikes are more likely stress‑related.
- Timing of GLP‑1 Dose: If the most recent GLP‑1 injection was within 24 hours, anticipate a modest insulin‑boosting effect that may temper hyperglycaemia.
- Concurrent Medications: Identify other glucose‑lowering drugs. When insulin or sulfonylureas are present, consider a lower glucose target (e.g., 140–180 mg/dL) to avoid hypoglycaemia.
- Type of Anesthesia: Regional techniques (spinal, epidural) often produce less catecholamine surge than general anesthesia, which may result in milder glucose elevations.
Practical Strategies for Glucose Monitoring During Surgery
Implementing a systematic approach can improve safety and outcomes:
- Pre‑operative Assessment
- Document the specific GLP‑1 agent, dose, and timing of the last dose.
- Confirm adherence to fasting guidelines, accounting for delayed gastric emptying.
- Review recent HbA1c and fasting glucose values to gauge baseline control.
- Intra‑operative Monitoring
- Obtain a baseline glucose reading after induction of anesthesia.
- Repeat measurements every 60–90 minutes, or more frequently if glucose drifts outside the target range (generally 140–180 mg/dL for most surgical patients).
- Use point‑of‑care glucometers calibrated for the operating‑room environment.
- Therapeutic Interventions
- If glucose rises above the target range, consider short‑acting insulin (e.g., regular insulin) administered intravenously, titrated to the glucose level and anticipated surgical stress.
- If glucose falls below 100 mg/dL, promptly treat with a dextrose‑containing solution (e.g., 5 % dextrose) and reassess the need for ongoing insulin.
- Avoid routine discontinuation of GLP‑1 agents on the day of surgery unless the patient is receiving high‑dose insulin or has a high risk of aspiration.
- Post‑operative Care
- Re‑evaluate glucose trends in the recovery area, as the stress response may persist for several hours.
- Resume the patient’s usual GLP‑1 regimen once oral intake is tolerated, unless contraindicated by surgical factors.
Frequently Asked Questions
Can GLP‑1 agonists cause intra‑operative hypoglycaemia?
While GLP‑1 agents have a low intrinsic risk of hypoglycaemia, the combination with insulin or sulfonylureas can increase this risk, especially during prolonged fasting or when surgical stress is minimal. Continuous monitoring and appropriate insulin adjustments are essential.
Should I hold my weekly Ozempic dose before surgery?
Most guidelines suggest that the weekly dose of Ozempic does not need to be held, as its long‑acting nature provides steady glucose control. However, individual circumstances—such as the type of surgery or concurrent insulin therapy—may warrant a clinician‑guided decision.
How does delayed gastric emptying from GLP‑1 affect anesthesia induction?
Slower gastric emptying can increase the volume of gastric contents, raising aspiration risk. Anesthesiologists should verify that the patient has adhered to an extended fasting period (often 8 hours for solids) and consider rapid‑sequence induction if needed.
What glucose target should be used for patients on GLP‑1 therapy?
General surgical guidelines recommend maintaining glucose between 140 and 180 mg/dL. For patients on GLP‑1 agonists without additional insulin or sulfonylureas, this range remains appropriate. Adjustments may be required based on individual risk factors and intra‑operative trends.
Getting Started with GLP‑1
If you or a loved one are considering GLP‑1 therapy for diabetes or weight management, the first step is to determine eligibility. Certified healthcare providers can evaluate your medical history, current medications, and treatment goals to see if a GLP‑1 agonist such as Ozempic, Wegovy, Mounjaro, or Zepbound is appropriate.
To streamline the process, you can check your eligibility here. A licensed online provider will guide you through any required lab work, discuss potential side effects, and help you understand how GLP‑1 therapy fits into your overall health plan.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about medication, anesthesia, or any medical treatment.